Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Mol Cancer Ther
; 21(3): 397-406, 2022 03 01.
Article
in En
| MEDLINE
| ID: mdl-34965958
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Histone Deacetylase Inhibitors
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Mol Cancer Ther
Journal subject:
ANTINEOPLASICOS
Year:
2022
Document type:
Article
Country of publication:
United States